secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001213900-26-016474
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics issues $937.5k convertible note, dismisses auditor Wolf & Co., appoints Eric Francois to board
--------------------------------------------------------------------------------

- Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.
- Dismissed Wolf & Company, P.C. as auditor effective Feb 13, 2026; no disagreements, but prior material weakness in internal controls noted.
- Appointed Salberg & Company, P.A. as new auditor effective Feb 13, 2026.
- Appointed Eric Francois to board, increasing size to 7; he served as Managing Director at Raymond James, CFO at Scynexis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/0001213900-26-016474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/ea0276984-8k_ceroa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-016474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer